Evidence map›Paper›PMID 27546041›Full record

ArticleMolecular informatics2016

Further Insights in the Binding Mode of Selective Inhibitors to Human PDE4D Enzyme Combining Docking and Molecular Dynamics.

Pasqualina D'Ursi, Sara Guariento, Gabriele Trombetti, Alessandro Orro, Elena Cichero, Luciano Milanesi, Paola Fossa, Olga Bruno

Open access · hybridAbstract read
In one paragraph

Article in Molecular informatics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Frontiers in pharmacology · 2018
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Pasqualina D'UrsiInstitute for Biomedical Technologies e National Research Council (ITB-CNR), Via Fratelli Cervi 93, 20090, Segrate (MI, Italy.
Sara GuarientoDepartment of Pharmacy, Section of Medicinal Chemistry, School of Medical and Pharmaceutical Sciences, University of Genoa, Viale Benedetto XV 3, 16132, Genova (GE, Italy.
Gabriele TrombettiInstitute for Biomedical Technologies e National Research Council (ITB-CNR), Via Fratelli Cervi 93, 20090, Segrate (MI, Italy.
Alessandro OrroInstitute for Biomedical Technologies e National Research Council (ITB-CNR), Via Fratelli Cervi 93, 20090, Segrate (MI, Italy.
Elena CicheroDepartment of Pharmacy, Section of Medicinal Chemistry, School of Medical and Pharmaceutical Sciences, University of Genoa, Viale Benedetto XV 3, 16132, Genova (GE, Italy.
Luciano MilanesiInstitute for Biomedical Technologies e National Research Council (ITB-CNR), Via Fratelli Cervi 93, 20090, Segrate (MI, Italy.
Paola FossaDepartment of Pharmacy, Section of Medicinal Chemistry, School of Medical and Pharmaceutical Sciences, University of Genoa, Viale Benedetto XV 3, 16132, Genova (GE, Italy . fossap@unige.it.
Olga BrunoDepartment of Pharmacy, Section of Medicinal Chemistry, School of Medical and Pharmaceutical Sciences, University of Genoa, Viale Benedetto XV 3, 16132, Genova (GE, Italy.
University of Genoa · ITNational Academies of Sciences, Engineering, and Medicine · USInstitute of Biomedical Technologies · ITNational Research Council · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease has recently emerged as a possible field of application for PDE4D inhibitors (PDE4DIs). The great structure similarity among the various PDE4 isoforms and, furthermore, the lack of the full length crystal structure of the enzyme, impaired the rational design of new selective PDE4DIs. In this paper, with the aim of exploring new insights into the PDE4D binding, we tackled the problem by performing a computational study based on docking simulations combined with molecular dynamics (D-MD). Our work uniquely identified the binding mode and the key residues involved in the interaction with a number of in-house catechol iminoether derivatives, acting as PDE4DIs. Moreover, the new binding mode was tested using a series of analogues previously reported by us and it was used to confirm their key structural features to allow PDE4D inhibition. The binding model disclosed within the current computational study may prove to be useful to further advance the design and synthesis of novel, more potent and selective, PDE4D inhibitors.

Indexed as

Binding SitesCyclic Nucleotide Phosphodiesterases, Type 4Enzyme InhibitorsHumansMolecular Docking SimulationMolecular Dynamics SimulationProtein BindingProtein IsoformsCyclic Nucleotide Phosphodiesterases, Type 4Enzyme InhibitorsPDE4D protein, humanProtein Isoformsdockingmolecular dynamicsPDE4PDE4D selective inhibitorsPhosphodiesterases

Identifiers

PMID27546041
PMCPMC5094559
OpenAlexW2473159792

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.